Evaluating FVIII Doses for Immune Tolerance in Hemophilia A Boys with Inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess different doses and frequencies of FVIII (Advate) administration for immune tolerance induction in boys with severe Hemophilia A who have developed inhibitors. The research focuses on understanding how varying treatment regimens can effectively eradicate these inhibitors, which hinder the efficacy of standard FVIII replacement therapy. By monitoring the patients' responses to the treatment, the study seeks to establish optimal dosing strategies that could improve patient outcomes and reduce bleeding episodes. The study is conducted at Beijing Children's Hospital, involving a targeted patient population with specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Severe hemophilia A (FⅧ:C \<2%);
* Positive for FVIII inhibitors;
* No allergic reactions to FVIII concentrates.

Exclusion Criteria:

* Presence of other coagulation-related diseases,
* Hematological disorders,
* autoimmune diseases
* malignancies

Where it's running

• Beijing Children's hospitial
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Dr. Wu
• Email: runhuiwu@hotmail.com
• Phone: +86 010-59616623

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for Hemophilia A in Adolescents and Adults with High Titer Inhibitor

  This study is testing if a new treatment for hemophilia A, using a drug called SCT800 alone or with another drug called Daratumumab, can help teenagers and adults with high titer inhibitors feel better and have fewer relapses.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05888870

• Using SEVENFACT® to treat bleeding in hemophilia patients with inhibitors

  This study is testing if SEVENFACT® can safely help people aged 12 and older with hemophilia who have inhibitors stop bleeding during episodes.

  Recruiting at 15 sites Phase 4 American Thrombosis and Hemostasis Network · Phoenix, Arizona and 20 other locations · NCT04647227

• Evaluating the effects of a treatment on bone health in patients with severe hemophilia A

  This study is testing how a new treatment for severe hemophilia A affects bone and joint health over time to help make monitoring easier for patients.

  Recruiting Tri-Service General Hospital (TSGH) · Taipei, Neihu Dist. · NCT05981274

• Understanding antibody changes in hemophilia A patients treated with emicizumab

  This study looks at how the immune system reacts to emicizumab treatment in people with severe hemophilia A by checking leftover samples from their regular doctor visits.

  Recruiting Goethe University · Frankfurt am Main, Hesse · NCT05802836

• Looking at chronic pain in adults with severe haemophilia A

  This project will see if chronic pain in adults with severe haemophilia A who have been on bispecific monoclonal antibodies is linked to pain catastrophising, confidence in managing pain, and body image.

  Recruiting Investigación en Hemofilia y Fisioterapia · Oviedo, Principality of Asturias · NCT07096349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.